Literature DB >> 17310110

Deoxygenation-induced non-electrolyte pathway in red cells from sickle cell patients.

Joseph A Browning1, Hannah C Robinson, J Clive Ellory, John S Gibson.   

Abstract

Red cells from patients with sickle cell disease contain HbS rather than the normal HbA (here termed HbS cells). On deoxygenation, HbS cells exhibit a distinctive solute permeability pathway, P(sickle), activated stochastically, and partially inhibited by DIDS and dipyridamole. It is often referred to as a cation channel although its permeability characteristics remain vague and its molecular identity is unknown. We show that, in contrast to normal red cells, a proportion of HbS cells underwent haemolysis when deoxygenated in isosmotic non-electrolyte solutions. Haemolysis was stochastic: cells unlysed after an initial deoxygenation pulse showed lysis when harvested, reoxygenated and subsequently exposed to a second period of deoxygenation. O(2) dependence of haemolysis was similar to that of P(sickle) activation. Haemolysis was accompanied by high rates of sucrose influx, and both haemolysis and sucrose influx were inhibited by DIDS and dipyridamole. Sucrose influx was only detected as ionic strength was reduced below 80 mM. These findings are consistent with the postulate that deoxygenation of HbS cells, under certain conditions, activates a novel non-electrolyte pathway. Their significance lies in understanding the nature of the deoxygenation-induced permeability in HbS cells, together with its relationship with novel pathways induced by a variety of manipulations in normal red cells. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310110     DOI: 10.1159/000099204

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  9 in total

1.  Harnessing red cell membrane pathophysiology towards point-of-care diagnosis for sickle cell disease.

Authors:  Seth L Alper
Journal:  J Physiol       Date:  2013-03-15       Impact factor: 5.182

2.  A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease.

Authors:  C Milligan; D C Rees; J C Ellory; A Osei; J A Browning; A Hannemann; J S Gibson
Journal:  J Physiol       Date:  2013-01-07       Impact factor: 5.182

3.  The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype).

Authors:  A Hannemann; E Weiss; D C Rees; S Dalibalta; J C Ellory; J S Gibson
Journal:  Anemia       Date:  2010-10-13

Review 4.  Triggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte death.

Authors:  Elisabeth Lang; Florian Lang
Journal:  Biomed Res Int       Date:  2015-03-04       Impact factor: 3.411

5.  The effect of xanthine oxidase and hypoxanthine on the permeability of red cells from patients with sickle cell anemia.

Authors:  Halima W M Al Balushi; David C Rees; John N Brewin; Anke Hannemann; John S Gibson
Journal:  Physiol Rep       Date:  2018-03

6.  The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.

Authors:  Halima Al Balushi; Kobina Dufu; David C Rees; John N Brewin; Anke Hannemann; Donna Oksenberg; David C-Y Lu; John S Gibson
Journal:  Physiol Rep       Date:  2019-03

7.  The Effect of Antioxidants on the Properties of Red Blood Cells From Patients With Sickle Cell Anemia.

Authors:  Halima Al Balushi; Anke Hannemann; David Rees; John Brewin; John Stanley Gibson
Journal:  Front Physiol       Date:  2019-08-13       Impact factor: 4.566

8.  Identification of the Ca²⁺ entry pathway involved in deoxygenation-induced phosphatidylserine exposure in red blood cells from patients with sickle cell disease.

Authors:  U M Cytlak; A Hannemann; D C Rees; J S Gibson
Journal:  Pflugers Arch       Date:  2013-06-18       Impact factor: 3.657

9.  Validation of a Low-Cost Paper-Based Screening Test for Sickle Cell Anemia.

Authors:  Nathaniel Z Piety; Xiaoxi Yang; Julie Kanter; Seth M Vignes; Alex George; Sergey S Shevkoplyas
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.